Abstract Background Immune checkpoint inhibitors (ICIs) have revolutionized the cancer
therapeutic landscape and our perception of interactions between the immune system and …

An improved understanding of the anti-tumor CD8+ T cell response after checkpoint
blockade would enable more informed and effective therapeutic strategies. Here we …

Despite encouraging results with immune checkpoint inhibition (ICI), a large fraction of
cancer patients still does not achieve clinical benefit. Finding predictive markers in the …

Checkpoint blockade immunotherapy has become a first-line treatment option for cancer
patients, with success in increasingly diverse cancer types. Still, many patients do not …

Cancer immunotherapy with monoclonal antibodies directed against regulatory pathways in
T lymphocytes has been revolutionizing medical oncology, and the clinical success of …

Immune checkpoint blockade represents the latest revolution in cancer treatment by
substantially increasing patients' lifetime and quality of life in multiple neoplastic …

Responsiveness to immune checkpoint blockade (ICB) therapy in cancer is currently
predicted by disparate individual measures–with varying degrees of accuracy–including …

Background The temporal response to checkpoint blockade (CB) is incompletely
understood. Here, we profiled the tumor infiltrating lymphocyte (TIL) landscape in response …

The tumor immune contexture plays a major role for the clinical outcome of patients. High
densities of CD45RO+ T helper 1 cells and CD8+ T cells are associated with improved …

Background Immune cell-driven anti-cancer activity is paramount for effective responses to
checkpoint inhibitors (ICB). However, the contribution of the different immune cell subsets in …